Trial Profile
Open-label phase IIa pilot study exploring safety and potential efficacy of recombinant human erythropoietin in early mild Alzheimer Dementia and therapy-refractory Major Depression ("EPO-AD")
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2012
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Alzheimer's disease; Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Acronyms EPO-AD
- 04 May 2012 New trial record